K. Papadopoulos

1.4k total citations
56 papers, 1.1k citations indexed

About

K. Papadopoulos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, K. Papadopoulos has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in K. Papadopoulos's work include Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). K. Papadopoulos is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). K. Papadopoulos collaborates with scholars based in United States, Spain and Australia. K. Papadopoulos's co-authors include Anthony W. Tolcher, Amita Patnaik, Alain C. Mita, Johann S. de Bono, David Olmos, Pamela Bartels, Anne Keating, Lionel D. Lewis, Chris H. Takimoto and Christopher R. Garrett and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

K. Papadopoulos

55 papers receiving 1.1k citations

Peers

K. Papadopoulos
J. Rafael Sierra United States
A. W. Tolcher United States
Analía Azaro Spain
Laurence Cooke United States
Christopher Ruel United States
Stefanie Avril United States
Luigi Manenti United States
Meredith McKean United States
Samuel W. Brady United States
Ecaterina E. Dumbrava United States
J. Rafael Sierra United States
K. Papadopoulos
Citations per year, relative to K. Papadopoulos K. Papadopoulos (= 1×) peers J. Rafael Sierra

Countries citing papers authored by K. Papadopoulos

Since Specialization
Citations

This map shows the geographic impact of K. Papadopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Papadopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Papadopoulos more than expected).

Fields of papers citing papers by K. Papadopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Papadopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Papadopoulos. The network helps show where K. Papadopoulos may publish in the future.

Co-authorship network of co-authors of K. Papadopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of K. Papadopoulos. A scholar is included among the top collaborators of K. Papadopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Papadopoulos. K. Papadopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jänne, Pasi A., Kathryn C. Arbour, Jordi Rodón, et al.. (2025). OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007. Journal of Thoracic Oncology. 20(10). S25–S26.
2.
Jänne, Pasi A., Jason T. Henry, K. Papadopoulos, et al.. (2024). 503LBA LBA Orals: Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del). European Journal of Cancer. 211. 114981–114981. 2 indexed citations
3.
4.
Garon, Edward B., David T. Wong, Jeffrey Schneider, et al.. (2018). MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-PD-1. Journal of Thoracic Oncology. 13(10). S366–S367. 1 indexed citations
5.
Tolcher, Anthony W., K. Papadopoulos, Sreenivasa R Chandana, et al.. (2018). A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate. Annals of Oncology. 29. iii8–iii8. 5 indexed citations
6.
Hecht, J. Randolph, Aung Naing, Gerald S. Falchook, et al.. (2017). Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX). Annals of Oncology. 28. v254–v254. 1 indexed citations
7.
Wong, Deborah J., Jeffrey Schneider, Raid Aljumaily, et al.. (2017). PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC. Annals of Oncology. 28. xi3–xi3. 1 indexed citations
8.
Naing, Aung, Jon Infante, Deborah J. Wong, et al.. (2017). Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial. Annals of Oncology. 28. xi1–xi1. 1 indexed citations
9.
Naing, Aung, Jeffrey R. Infante, K. Papadopoulos, et al.. (2015). PEGylated human IL-10 (AM0010) in advanced solid tumors. Annals of Oncology. 26. viii1–viii1. 2 indexed citations
10.
Shimizu, Toshio, Patricia LoRusso, K. Papadopoulos, et al.. (2014). Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(19). 5032–5040. 67 indexed citations
11.
Papadopoulos, K., et al.. (2014). 96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen. European Journal of Cancer. 50. 35–35. 1 indexed citations
12.
Sandhu, Shahneen, K. Papadopoulos, Peter C.C. Fong, et al.. (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(4). 1041–1050. 228 indexed citations
13.
Tolcher, Anthony W., Christopher J. Sweeney, K. Papadopoulos, et al.. (2011). Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. Clinical Cancer Research. 17(2). 363–371. 67 indexed citations
14.
Mita, Alain C., K. Papadopoulos, Maja J.A. de Jonge, et al.. (2011). Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer. 105(7). 938–944. 36 indexed citations
15.
16.
17.
Mita, Monica, Lorrin Yee, K. Papadopoulos, et al.. (2008). 42 POSTER NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort. European Journal of Cancer Supplements. 6(12). 17–17. 1 indexed citations
18.
Tolcher, Anthony W., Alain C. Mita, Lionel D. Lewis, et al.. (2008). Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. Journal of Clinical Oncology. 26(32). 5198–5203. 208 indexed citations
19.
LoRusso, Patricia, Lorrin Yee, K. Papadopoulos, et al.. (2007). Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. Molecular Cancer Therapeutics. 6. 1 indexed citations
20.
Papadopoulos, K.. (2006). Targeting the Bcl-2 Family in Cancer Therapy. Seminars in Oncology. 33(4). 449–456. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Rafael Sierra Breakdown of academic impact, for papers by A. W. Tolcher Breakdown of academic impact, for papers by Analía Azaro Breakdown of academic impact, for papers by Laurence Cooke Breakdown of academic impact, for papers by Christopher Ruel Breakdown of academic impact, for papers by Stefanie Avril Breakdown of academic impact, for papers by Luigi Manenti Breakdown of academic impact, for papers by Meredith McKean Breakdown of academic impact, for papers by Samuel W. Brady Breakdown of academic impact, for papers by Ecaterina E. Dumbrava
Rankless by CCL
2026